Antibody Drug Conjugates: Nonclinical Safety Considerations
- 30 May 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 17 (5), 1055-1064
- https://doi.org/10.1208/s12248-015-9790-0
Abstract
Antibody drug conjugates (ADCs) are biopharmaceutical molecules consisting of a cytotoxic small molecule covalently linked to a targeted protein carrier via a stable cleavable or noncleavable linker. The process of conjugation yields a highly complex molecule with biochemical properties that are distinct from those of the unconjugated components. The impact of these biochemical differences on the safety and pharmacokinetic (PK) profile of the conjugate must be considered when determining the types of nonclinical safety studies required to support clinical development of ADCs. The hybrid nature of ADCs highlights the need for a science-based approach to safety assessment that incorporates relevant aspects of small and large molecule testing paradigms. This thinking is reflected in current regulatory guidelines, where sections pertaining to conjugates allow for a flexible approach to nonclinical safety testing. The aim of this article is to review regulatory expectations regarding early assessment of nonclinical safety considerations and discuss how recent advances in our understanding of ADC-mediated toxicity can be used to guide the types of nonclinical safety studies needed to support ADC clinical development. The review will also explore nonclinical testing strategies that can be used to streamline ADC development by assessing the safety and efficacy of next generation ADC constructs using a rodent screen approach.Keywords
This publication has 64 references indexed in Scilit:
- SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLBlood, 2013
- Antibody Drug Conjugates as Cancer TherapeuticsAntibodies, 2013
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2012
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaInvestigational New Drugs, 2011
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- The Pharmacologic Basis for Antibody-Auristatin Conjugate ActivityJournal of Pharmacology and Experimental Therapeutics, 2009
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Preclinical safety testing of monoclonal antibodies: the significance of species relevanceNature Reviews Drug Discovery, 2007
- Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in MiceJournal of Pharmacology and Experimental Therapeutics, 2003